Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer’s Disease
Journal of Medicinal Chemistry · 27.06.2024 · 67 (12) · 10248-10262
DOI: 10.1021/acs.jmedchem.4c00580 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 07.06.2024. Verfasst von Martin Pettersson und 29 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States. Hauptthemen laut MEDLINE: Amyloid Precursor Protein Secretases, Alzheimer Disease, Amyloid beta-Peptides. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Herein, we describe the design and synthesis of γ-secretase modulator (GSM) clinical candidate PF-06648671 (22) for the treatment of Alzheimer's disease. A key component of the design involved a 2,5-cis-tetrahydrofuran (THF) linker to impart conformational rigidity and lock the compound into a putative bioactive conformation. This effort was guided using a pharmacophore model since crystallographic information was not available for the membrane-bound γ-secretase protein complex at the time of this work. PF-06648671 achieved excellent alignment of whole cell in vitro potency (Aβ42 IC50 = 9.8 nM) and absorption, distribution, metabolism, and excretion (ADME) parameters. This resulted in favorable in vivo pharmacokinetic (PK) profile in preclinical species, and PF-06648671 achieved a human PK profile suitable for once-a-day dosing. Furthermore, PF-06648671 was found to have favorable brain availability in rodent, which translated into excellent central exposure in human and robust reduction of amyloid β (Aβ) 42 in cerebrospinal fluid (CSF).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States.
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
ORCID-Profile: Martin Pettersson, Douglas S Johnson, Christopher W Am Ende, Christopher J Helal, Christopher J O'Donnell, Nandini C Patel, Tuan P Tran
Zitieren
APA
Pettersson, M., Johnson, D. S., Humphrey, J. M., Am Ende, C. W., Butler, T. W., Dorff, P. H., Efremov, I. V., Evrard, E., Green, M. E., Helal, C. J., Kauffman, G. W., Mullins, P. B., Navaratnam, T., O'Donnell, C. J., O'Sullivan, T. J., Patel, N. C., Stepan, A. F., Stiff, C. M., Subramanyam, C., …, & Verhoest, P. R. (2024). Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer’s Disease. Journal of Medicinal Chemistry, 67(12), 10248-10262. https://doi.org/10.1021/acs.jmedchem.4c00580
Vancouver
Pettersson M, Johnson DS, Humphrey JM, Am Ende CW, Butler TW, Dorff PH, et al. Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer’s Disease. Journal of Medicinal Chemistry. 2024;67(12):10248-10262. doi:10.1021/acs.jmedchem.4c00580
BibTeX
@article{Pettersson2024,
author = {Pettersson, Martin and Johnson, Douglas S and Humphrey, John M and Am Ende, Christopher W and Butler, Todd W and Dorff, Peter H and Efremov, Ivan V and Evrard, Edelweiss and Green, Michael E and Helal, Christopher J and Kauffman, Gregory W and Mullins, Patrick B and Navaratnam, Thayalan and O'Donnell, Christopher J and O'Sullivan, Theresa J and Patel, Nandini C and Stepan, Antonia F and Stiff, Cory M and Subramanyam, Chakrapani and Trapa, Patrick and Tran, Tuan P and Vetelino, Beth Cooper and Yang, Eddie and Xie, Longfei and Pustilnik, Leslie R and Steyn, Stefanus J and Wood, Kathleen M and Bales, Kelly R and Hajos-Korcsok, Eva and Verhoest, Patrick R},
title = {Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer’s Disease},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {12},
pages = {10248--10262},
doi = {10.1021/acs.jmedchem.4c00580}
}
EUVIMED